Thanks for the link bid. It just reinforces my views. What do...

Thanks for the link bid. It just reinforces my views. What do all these drugs have in common? Provisional approval in recent months – experimental drugs, restricted access through who I don’t know because my own GP’s policy is they are not prescribing anything. I would suggest most if not all of these drugs are available only to in/out patients of hospitals. One or two are early treatments requiring administering within 5 days of symptoms. Just not quite sure who will be administering in that timeframe when GPs are not prescribing. Maybe everyone should go to hospital day one regardless of how they feel.

So we get back to Viraleze as a simple first line of defence since early treatments are really a charade. It does look like there could be a growing market though for Viraleze to add a layer of protection given the research pointing towards growing negative efficacy of vaccines thanks to the inhibition of the natural immune system. I encourage you and anybody to follow the international research as there are some very informative studies and papers releasing results. This could have an impact on Viraleze's future practical advantage in the market. But I'd stick with the DEP platform as our primary hope. What year are we in now?